Scholarlink

Purpose <p>Diabetes mellitus (DM) increases the risk of cardiovascular diseases through oxidative stress (OS) and inflammation. This study investigates the cardioprotective effects of isorhamnetin (ISO) in streptozotocin (STZ)-induced diabetic rats.</p> Materials and methods <p>Forty male <i>Wistar albino</i> rats were randomly divided into four groups: Control, STZ, STZ + ISO, and ISO + STZ. DM was induced by a single intraperitoneal (i.p.) injection of 50&#xa0;mg/kg STZ. ISO (5&#xa0;mg/kg, i.p.) was administered either before or after STZ induction. Hemodynamic parameters were measured invasively, and electrocardiographic changes were recorded. Histopathological and biochemical analyses were performed on heart and aorta tissues. OS markers were evaluated.</p> Results <p>STZ-induced DM significantly increased heart rate and blood pressure, while ISO treatment alleviated these effects. Histopathological analysis showed ISO reduced myocardial and vascular damage, with ISO + STZ offering better protection than STZ + ISO. ISO modulated OS markers: malondialdehyde levels varied by tissue and treatment group, while glutathione levels increased in diabetic groups. ISO pre-treatment also improved total antioxidant status and reduced total oxidant status and OS index levels. Additionally, ISO influenced serum cardiac markers, decreasing troponin-I and modulating myoglobin and pro-brain natriuretic peptide levels, indicating a cardioprotective effect.</p> Conclusion <p>ISO demonstrated significant cardioprotective effects by improving hemodynamic stability, reducing OS, and preventing histopathological damage in diabetic rats. Pre-treatment with ISO was more effective than post-treatment, suggesting its potential as a preventive agent against DM-related cardiovascular complications. Further clinical research is needed to confirm its therapeutic applicability.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Oxidative stress-related cardiovascular effects of isorhamnetin in streptozotocin-induced diabetes in rats

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月5日

查看全文
  • Onural Ozhan,
  • İrem Hatipoglu,
  • Muharrem Ucar,
  • Necip Ermis,
  • Azibe Yildiz,
  • Yusuf Turkoz,
  • Nigar Vardi,
  • Seyma Yasar,
  • Hakan Parlakpinar

摘要

Purpose

Diabetes mellitus (DM) increases the risk of cardiovascular diseases through oxidative stress (OS) and inflammation. This study investigates the cardioprotective effects of isorhamnetin (ISO) in streptozotocin (STZ)-induced diabetic rats.

Materials and methods

Forty male Wistar albino rats were randomly divided into four groups: Control, STZ, STZ + ISO, and ISO + STZ. DM was induced by a single intraperitoneal (i.p.) injection of 50 mg/kg STZ. ISO (5 mg/kg, i.p.) was administered either before or after STZ induction. Hemodynamic parameters were measured invasively, and electrocardiographic changes were recorded. Histopathological and biochemical analyses were performed on heart and aorta tissues. OS markers were evaluated.

Results

STZ-induced DM significantly increased heart rate and blood pressure, while ISO treatment alleviated these effects. Histopathological analysis showed ISO reduced myocardial and vascular damage, with ISO + STZ offering better protection than STZ + ISO. ISO modulated OS markers: malondialdehyde levels varied by tissue and treatment group, while glutathione levels increased in diabetic groups. ISO pre-treatment also improved total antioxidant status and reduced total oxidant status and OS index levels. Additionally, ISO influenced serum cardiac markers, decreasing troponin-I and modulating myoglobin and pro-brain natriuretic peptide levels, indicating a cardioprotective effect.

Conclusion

ISO demonstrated significant cardioprotective effects by improving hemodynamic stability, reducing OS, and preventing histopathological damage in diabetic rats. Pre-treatment with ISO was more effective than post-treatment, suggesting its potential as a preventive agent against DM-related cardiovascular complications. Further clinical research is needed to confirm its therapeutic applicability.